Complement in immune and inflammatory disorders: therapeutic interventions.
Complement in immune and inflammatory disorders: therapeutic interventions.
复制标题
DOI：
10.4049/jimmunol.1203200
复制
发表时间：
2013-04-15
期刊：
影响因子：
--
通讯作者：
Lambris JD
中科院分区：
文献类型：
--
作者：
Ricklin D;Lambris JD
随着认识到免疫炎症串扰是许多疾病的核心，对治疗此类疾病的新型免疫调节策略的需求急剧增长。作为免疫和炎症过程的主要引发剂和重要调节剂，补体系统已成为炎症性疾病早期和上游干预的有吸引力的靶标，并已成为药物发现的焦点。虽然普遍的条件，如年龄相关性黄斑变性吸引了最多的关注，补体介导的病理，具有不同的潜在机制，需要一个多方面的武器库的治疗策略。幸运的是，近年来的努力不仅将第一种补体抑制剂引入了临床，而且还为有希望的候选人填补了渠道。随着免疫调节策略的重点，这篇综述讨论了补体导向的治疗概念，并强调有前途的候选分子。
With the awareness that immune-inflammatory crosstalk is at the heart of many disorders, the desire for novel immunomodulatory strategies in the therapy of such diseases has grown dramatically. As a prime initiator and important modulator of immunological and inflammatory processes, the complement system has emerged as an attractive target for early and upstream intervention in inflammatory diseases and has moved into the spotlight of drug discovery. While prevalent conditions such as age-related macular degeneration have attracted the most attention, the diverse array of complement-mediated pathologies, with distinct underlying mechanisms, demands a multifaceted arsenal of therapeutic strategies. Fortunately, efforts in recent years have not only introduced the first complement inhibitors to the clinic but also filled the pipelines with promising candidates. With a focus on immunomodulatory strategies, this review discusses complement-directed therapeutic concepts and highlights promising candidate molecules.
登录
查看更多内容
影响因子：
4.4
作者：
Bora, Nalini S.;Kaliappan, Sankaranarayanan;Bora, Puran S.
通讯作者：
Bora, Puran S.
影响因子：
4.8
作者：
Hepburn, Natalie J.;Williams, Anwen S.;Harris, Claire L.
通讯作者：
Harris, Claire L.
影响因子：
3.5
作者：
Breivik, T.;Gundersen, Y.;Opstad, P. K.
通讯作者：
Opstad, P. K.
影响因子：
120.1
作者：
Drews, J
通讯作者：
Drews, J
影响因子：
3.4
作者：
Bestebroer J;Aerts PC;Rooijakkers SH;Pandey MK;Köhl J;van Strijp JA;de Haas CJ
通讯作者：
de Haas CJ